Results 1 to 10 of about 15,994,939 (300)

Modular delivery of co-stimulatory signals through a PD-1-based immunoswitch receptor improves the functionality of Hepatitis B Virus-specific engineered T cells [PDF]

Frontiers in Immunology
In chronic hepatitis B virus infection (cHBV), T-cell responses are skewed. This prevents the elimination of HBV-infected hepatocytes, contributes to hepatocellular carcinoma development, and limits the efficacy of T-cell therapies.
Luis Felipe Olguín-Contreras, Johanna Heep, Lisa Schiller, Eva Loffredo-Verde, Marvin M. Festag, Kai Metzger, Stephanie Färber, Merve Gültan, Margaret Tulessin, Susanne Wilde, Karin Wisskirchen, Karin Wisskirchen, Elfriede Noessner, Ulrike Protzer, Ulrike Protzer   +14 more
doaj   +2 more sources

Chimeric antigen receptors that trigger phagocytosis

eLife, 2018
Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The success of CAR-T cell therapies highlights the promise of programmed immunity and suggests that applying CAR strategies to other immune cell lineages may
Meghan A Morrissey, Adam P Williamson, Adriana M Steinbach, Edward W Roberts, Nadja Kern, Mark B Headley, Ronald D Vale   +6 more
doaj   +2 more sources

Engineering and Design of Chimeric Antigen Receptors

Molecular Therapy: Methods & Clinical Development, 2019
T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in blood cancers.
Sonia Guedan, Hugo Calderon, Avery D. Posey, Jr., Marcela V. Maus   +3 more
doaj   +2 more sources

Chimeric non-antigen receptors in T cell-based cancer therapy

Journal for ImmunoTherapy of Cancer, 2021
Adoptively transferred T cell-based cancer therapies have shown incredible promise in treatment of various cancers. So far therapeutic strategies using T cells have focused on manipulation of the antigen-recognition machinery itself, such as through ...
Andrew Kent, Eduardo Davila, Jitao Guo
doaj   +1 more source

HLA-independent T cell receptors for targeting tumors with low antigen density

Nature Medicine, 2022
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy.
J. Mansilla-Soto, Justin Eyquem, Sascha Haubner, Mohamad Hamieh, J. Feucht, Noémie Paillon, A. Zucchetti, Zhuoning Li, Maria Sjöstrand, P. Lindenbergh, M. Saetersmoen, A. Dobrin, Mathieu Maurin, A. Iyer, Andreina Garcia Angus, Matthew M. Miele, Ze-Guo Zhao, Theodoros Giavridis, Sjoukje J. C. van der Stegen, Fella Tamzalit, I. Rivière, M. Huse, R. Hendrickson, C. Hivroz, M. Sadelain   +24 more
semanticscholar   +1 more source

Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj   +1 more source

Toward high-throughput engineering techniques for improving CAR intracellular signaling domains

Frontiers in Bioengineering and Biotechnology, 2023
Chimeric antigen receptors (CAR) are generated by linking extracellular antigen recognition domains with one or more intracellular signaling domains derived from the T-cell receptor complex or various co-stimulatory receptors.
Savannah E. Butler, Savannah E. Butler, Colin J. Hartman, Colin J. Hartman, Yina H. Huang, Yina H. Huang, Margaret E. Ackerman, Margaret E. Ackerman   +7 more
doaj   +1 more source

Deep learning-based prediction of the T cell receptor-antigen binding specificity

Nature Machine Intelligence, 2021
Neoantigens play a key role in the recognition of tumour cells by T cells; however, only a small proportion of neoantigens truly elicit T-cell responses, and few clues exist as to which neoantigens are recognized by which T-cell receptors (TCRs).
Tianshi Lu, Ze Zhang, James Zhu, Yunguan Wang, Peixin Jiang, Xue Xiao, C. Bernatchez, J. Heymach, D. Gibbons, Jun Wang, Lin Xu, A. Reuben, Tao Wang   +12 more
semanticscholar   +1 more source

Long-term outcomes following CAR T cell therapy: what we know so far

Nature Reviews Clinical Oncology, 2023
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells to antigens expressed on cancer cells. CAR T cells are now an established treatment for patients with relapsed and/or refractory B cell lymphomas, B cell acute ...
Kathryn M. Cappell, J. Kochenderfer
semanticscholar   +1 more source

Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors

Frontiers in Immunology, 2020
Adaptive immune recognition is mediated by specific interactions between heterodimeric T cell receptors (TCRs) and their cognate peptide-MHC (pMHC) ligands, and the methods to accurately predict TCR:pMHC interaction would have profound clinical ...
Chloe H. Lee, Chloe H. Lee, Mariolina Salio, Giorgio Napolitani, Graham Ogg, Alison Simmons, Alison Simmons, Hashem Koohy, Hashem Koohy   +8 more
doaj   +1 more source